We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Speculation on what company will make a bid for beleaguered Bristol-Myers Squibb (BMS) has ramped up since billionaire activist investor Carl Icahn acquired an undisclosed number of shares based on takeover rumors.